Grifols, S.A. (NASDAQ:GRFS) Stock Position Reduced by Point72 Asset Management L.P.

Point72 Asset Management L.P. cut its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 22.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 465,768 shares of the biotechnology company's stock after selling 131,077 shares during the quarter. Point72 Asset Management L.P.'s holdings in Grifols were worth $4,136,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GRFS. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Grifols in the second quarter valued at about $359,000. Sei Investments Co. grew its stake in shares of Grifols by 4.7% in the second quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company's stock valued at $13,931,000 after buying an additional 100,131 shares in the last quarter. Melqart Asset Management UK Ltd acquired a new stake in shares of Grifols in the third quarter valued at about $1,628,000. Hantz Financial Services Inc. acquired a new stake in shares of Grifols in the second quarter valued at about $1,235,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Grifols in the third quarter valued at about $2,636,000.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded Grifols to a "strong-buy" rating in a research note on Tuesday, October 29th.

Grifols Price Performance

GRFS traded down $0.04 on Monday, reaching $7.26. The company's stock had a trading volume of 640,152 shares, compared to its average volume of 1,858,588. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The business's 50 day moving average is $8.60 and its 200 day moving average is $8.09.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.